- Home
- BNR vs COEP Comparison
BNR vs COEP Comparison
Compare BNR & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- COEP
- Stock Information
- Founded
- BNR 2014
- COEP 2017
- Country
- BNR China
- COEP United States
- Employees
- BNR N/A
- COEP N/A
- Industry
- BNR Medical Specialities
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BNR Health Care
- COEP Health Care
- Exchange
- BNR Nasdaq
- COEP Nasdaq
- Market Cap
- BNR 29.1M
- COEP 32.0M
- IPO Year
- BNR 2020
- COEP N/A
- Fundamental
- Price
- BNR $3.25
- COEP $10.41
- Analyst Decision
- BNR
- COEP
- Analyst Count
- BNR 0
- COEP 0
- Target Price
- BNR N/A
- COEP N/A
- AVG Volume (30 Days)
- BNR 68.1K
- COEP 67.0K
- Earning Date
- BNR 06-02-2025
- COEP 05-14-2025
- Dividend Yield
- BNR N/A
- COEP N/A
- EPS Growth
- BNR N/A
- COEP N/A
- EPS
- BNR N/A
- COEP N/A
- Revenue
- BNR $70,669,261.00
- COEP $62,874.00
- Revenue This Year
- BNR $136.32
- COEP N/A
- Revenue Next Year
- BNR N/A
- COEP N/A
- P/E Ratio
- BNR N/A
- COEP N/A
- Revenue Growth
- BNR N/A
- COEP N/A
- 52 Week Low
- BNR $2.18
- COEP $2.31
- 52 Week High
- BNR $7.90
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- BNR 57.77
- COEP 57.75
- Support Level
- BNR $2.49
- COEP $9.11
- Resistance Level
- BNR $3.05
- COEP $10.00
- Average True Range (ATR)
- BNR 0.34
- COEP 0.61
- MACD
- BNR 0.15
- COEP 0.15
- Stochastic Oscillator
- BNR 87.61
- COEP 85.25
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.